Cyclofem/Cyclo-Provera: emerging countries' perspective
Int J Gynaecol Obstet
; 62(Suppl. 1): S31-6, Aug. 1998.
Article
em En
| MedCarib
| ID: med-1402
Biblioteca responsável:
JM3.1
Localização: JM3.1; RG1.15
ABSTRACT
Cyclo-Provera, the original name of the combination of 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate, later known as Cyclofem and hereafter referred to MPA/E2C, has proven its use- effectiveness (pregnancy rate less than 1 percent) in routine service delivery conditions. Overall, the life-table discontinuation rates at 1 year ranged from 33.5 percent to 71.8 percent. Only a third of total discontinuations were attributable to the injectable contraceptive method, thus raising the importance of service delivery issues related to its continued use. The results of introductory trials in Mexico, Indonesia, Thailand, Tunisia, Jamaica and, more recently, Brazil, Colombia, Chile and Peru have demonstrated that MPA/E2C is a highly effective contraceptive that could be offered as an alternative to current fertility regulation methods for many women around the world. In addition, the results of studies were the basis for the approval of MPA/E2C by local health authorities and its inclusion in the Ministries of Health Family Planning Programs.(Au)
Buscar no Google
Coleções:
01-internacional
Base de dados:
MedCarib
Assunto principal:
Conhecimentos, Atitudes e Prática em Saúde
/
Acetato de Medroxiprogesterona
/
Anticoncepcionais Femininos
/
Países em Desenvolvimento
/
Estradiol
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Aspecto:
Determinantes_sociais_saude
/
Equity_inequality
Limite:
Female
/
Humans
Idioma:
En
Revista:
Int J Gynaecol Obstet
Ano de publicação:
1998
Tipo de documento:
Article